Manufacturers in China have traditionally made low-cost generics for domestic use. But they see sales in the US — the world’s largest generics market, worth $114bn in 2017 — as a way to boost revenues and prove their quality to Chinese patients who place greater trust in imported drugs.
传统上,中国制药公司制造的低成本仿制药供应国内市场。但中国药企认为,把产品投放美国市场是一条提升收入、并向更信任进口药的中国患者证明其产品质量的途径。美国是世界最大的仿制药市场,2017年市场规模达到1140亿美元。
Increased generics exports contributed to an 8 per cent year-on-year rise in exports of western medicines from China in 2017 to $3.5bn, according to Chinese officials, though that figure includes drugs made by multinationals in China.
据中国官员介绍,仿制药出口增加帮助中国在2017年实现西药出口同比增长8%,至35亿美元,尽管该数据包含了在华经营的跨国公司制造的药品。
“From a manufacturing standpoint, many Chinese facilities have approval from the FDA or European drug authorities, so are on the same level as overseas companies,” said John Lin, a partner at consultancy Roland Berger.
“从生产角度而言,很多中国药厂已经获得了美国FDA或者欧洲药品监管机构的批准,因此与海外公司处于同一水平,”咨询机构罗兰贝格(Roland Berger)合伙人林江翰(John Lin)说。
【中国药企热衷对美出口仿制药】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15